BURLINGTON, Mass.– Myomo, Inc. (NYSE American: MYO), a leading provider of wearable medical robotics for individuals with neurological disorders and upper-limb paralysis, has announced upcoming changes to its Board of Directors.
Directors Amy Knapp and Yitzchak Jacobovitz have informed the company that they will not seek re-election as Class II directors. Knapp, who joined the board in July 2016, and Jacobovitz, who became a director in January 2023, will both conclude their terms at the company’s 2025 Annual Meeting, scheduled for June.
“I’m grateful for the insights and contributions Amy and Yitz have provided the board during their tenures,” said Paul R. Gudonis, chairman and CEO of Myomo. “We plan to name additional directors in the future as we continue to evolve Myomo’s governance and strategic oversight.”
Knapp reflected positively on her time with the company, stating, “It has been a privilege to serve on Myomo’s board and I’m gratified to have played a role in the growth and success of the company to date. With the achievement of Medicare Part B coverage for the MyoPro™ and an outstanding leadership team, I believe the future is bright for Myomo.” She added that she will continue to advise the company on reimbursement matters.
Jacobovitz expressed confidence in Myomo’s direction and outlook: “I am highly confident in the Company’s strategic direction, its financial position and its trajectory toward achieving sustainable positive cash flow.” He will remain involved with Myomo as a non-voting board observer.
The company has not yet announced replacements but indicated plans to appoint new directors as part of its ongoing governance strategy.
